[Prognostic significance of early molecular response after second-line treatment with dasatinib of chronic myeloid leukemia patients].
作者信息
Chen Y L, Meng L, Yan G L, Yang Z Z, Huang Z P, Zhang Y S, Zhao Z, Wang C C, Bao Y, Xiang H, Yin H, Chen L F, Xiong Y Y, Wang L, Li W M
机构信息
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):608-611. doi: 10.3760/cma.j.issn.0253-2727.2019.07.015.
Abstract
摘要
相似文献
1
[Prognostic significance of early molecular response after second-line treatment with dasatinib of chronic myeloid leukemia patients].[达沙替尼二线治疗慢性髓性白血病患者后早期分子反应的预后意义]
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):608-611. doi: 10.3760/cma.j.issn.0253-2727.2019.07.015.
2
Reactive follicular hyperplasia on dasatinib treatment for chronic myeloid leukemia.达沙替尼治疗慢性髓性白血病时出现的反应性滤泡增生
Ann Hematol. 2017 Nov;96(11):1953-1954. doi: 10.1007/s00277-017-3105-8. Epub 2017 Aug 19.
3
Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients.尼洛替尼与达沙替尼二线治疗慢性期慢性髓性白血病患者的真实世界比较。
Ann Hematol. 2021 May;100(5):1213-1219. doi: 10.1007/s00277-021-04477-0. Epub 2021 Mar 7.
4
Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.一线达沙替尼治疗新诊断慢性期慢性髓性白血病的临床疗效与安全性以及BCR-ABL1转录本下降速度与实现分子反应的相关性：顺天堂山梨合作研究组报告
Oncology. 2018;94(2):85-91. doi: 10.1159/000481945. Epub 2017 Nov 18.
5
Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.达沙替尼治疗慢性期慢性髓性白血病患者中 BCR-ABL1 转录本的快速减少可预测深度分子反应。
Eur J Haematol. 2018 Jan;100(1):27-35. doi: 10.1111/ejh.12969. Epub 2017 Oct 16.
6
Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day).酪氨酸激酶抑制剂用于慢性期慢性髓性白血病的剂量：关于达沙替尼（50毫克/天）和波纳替尼（15毫克/天）低剂量起始治疗的情况
Am J Hematol. 2022 Nov;97(11):1394-1397. doi: 10.1002/ajh.26695. Epub 2022 Sep 5.
7
Long-term results of frontline dasatinib in chronic myeloid leukemia.一线达沙替尼治疗慢性髓性白血病的长期结果。
Cancer. 2020 Apr 1;126(7):1502-1511. doi: 10.1002/cncr.32627. Epub 2020 Jan 30.
8
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.慢性期慢性髓性白血病伊马替尼不耐受患者中对达沙替尼的交叉不耐受
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):341-349.e1. doi: 10.1016/j.clml.2016.03.004. Epub 2016 Mar 29.
9
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.达沙替尼可快速诱导伊马替尼治疗后 BCR-ABL1 转录本可检测到的慢性期慢性髓性白血病患者获得主要分子学反应的深层分子反应。
Int J Clin Oncol. 2017 Oct;22(5):972-979. doi: 10.1007/s10147-017-1141-y. Epub 2017 May 26.
10
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.达沙替尼用于对伊马替尼耐药或不耐受的慢性期慢性髓性白血病患者：CA180-034研究的7年随访
Am J Hematol. 2016 Sep;91(9):869-74. doi: 10.1002/ajh.24423. Epub 2016 Jun 20.
本文引用的文献
1
[Analysis of Efficacy and Related Factors of Acquired Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with TKI].[酪氨酸激酶抑制剂治疗慢性髓性白血病患者获得性深度分子反应的疗效及相关因素分析]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Dec;25(6):1597-1604. doi: 10.7534/j.issn.1009-2137.2017.06.003.
2
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.伊马替尼治疗慢性髓性白血病的长期疗效
N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.
3
BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.伊马替尼治疗失败后，采用二线第二代酪氨酸激酶抑制剂治疗时，3个月和6个月时的BCR-ABL1转录水平更有助于识别预后不良的慢性髓性白血病患者：单机构报告
Acta Haematol. 2015;134(4):248-54. doi: 10.1159/000430835.
4
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.达沙替尼治疗开始后1个月或3个月时的分子反应疗效，可预测慢性期伊马替尼耐药或不耐受的日本慢性粒细胞白血病患者对达沙替尼的反应改善情况。
J Clin Exp Hematop. 2014;54(3):197-204. doi: 10.3960/jslrt.54.197.
5
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.达沙替尼治疗伊马替尼治疗失败的慢性期慢性髓性白血病的长期疗效：一项 3 期研究的随访。
Blood. 2014 Apr 10;123(15):2317-24. doi: 10.1182/blood-2013-10-532341. Epub 2014 Feb 25.
6
BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.BCR-ABL1 转录本在 3 个月时可预测伊马替尼治疗失败的慢性期慢性髓性白血病患者接受第二代酪氨酸激酶抑制剂治疗后的长期结局。
Br J Haematol. 2013 Mar;160(5):630-9. doi: 10.1111/bjh.12187. Epub 2012 Dec 24.
7
Ponatinib in refractory Philadelphia chromosome-positive leukemias.波纳替尼治疗难治性费城染色体阳性白血病。
N Engl J Med. 2012 Nov 29;367(22):2075-88. doi: 10.1056/NEJMoa1205127.
8
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.二线酪氨酸激酶抑制剂的应答持久：慢性髓性白血病患者的意向治疗分析。
Blood. 2012 Feb 23;119(8):1838-43. doi: 10.1182/blood-2011-10-383000. Epub 2011 Dec 14.
9
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.慢性髓性白血病：欧洲白血病网络概念与管理建议的更新
J Clin Oncol. 2009 Dec 10;27(35):6041-51. doi: 10.1200/JCO.2009.25.0779. Epub 2009 Nov 2.
10
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.达沙替尼用于伊马替尼耐药的费城染色体阳性白血病。
N Engl J Med. 2006 Jun 15;354(24):2531-41. doi: 10.1056/NEJMoa055229.
Zotero 插件